GlassScriptPhysician profile
Barry J Mccasland
NPI 1073514063
$28,829.93
in general payments reported to CMS, 2019-2025
64 companies · $3,091 in 2025
The $3,091 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,823 · 2020: $2,202 · 2021: $3,772 · 2022: $3,675 · 2023: $9,491 · 2024: $3,776 · 2025: $3,091.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $4,340 · Travel and Lodging: $954 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500 · Education: $23.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,540.26 |
| Consulting Fee | $4,340.00 |
| Travel and Lodging | $954.33 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
| Education | $23.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $6,448.17 | 2019-2025 | Kesimpta |
| Abbvie INC. | $1,888.75 | 2019-2025 | |
| Biogen, INC. | $1,603.87 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Pfizer INC. | $1,450.39 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,384.91 | 2019-2025 | Ajovy, Austedo, Austedo Xr |
| Emd Serono, INC. | $1,253.09 | 2019-2025 | Mavenclad |
| Mdd US Operations, LLC | $1,237.01 | 2019-2025 | Apokyn, Gocovri, Qelbree |
| Ucb, INC. | $1,177.70 | 2019-2025 | Briviact, Nayzilam, Zilbrysq |
| Sunovion Pharmaceuticals INC. | $780.14 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $680.05 | 2019-2025 | Ingrezza, Ongentys |
| Kyowa Kirin, INC. | $597.12 | 2020-2025 | Nourianz |
| Lilly USA, LLC | $586.01 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Upsher-Smith Laboratories LLC | $540.33 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $535.75 | 2019-2025 | Qelbree |
| Amgen INC. | $521.65 | 2019-2025 | Uplizna, Aimovig |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $511.78 | 2020-2025 | |
| Lundbeck LLC | $486.94 | 2019-2025 | Vyepti |
| Celgene Corporation | $462.82 | 2021-2024 | Zeposia |
| Amneal Pharmaceuticals LLC | $418.96 | 2019-2025 | Crexont, Rytary |
| Genentech USA, INC. | $415.56 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Horizon Therapeutics Plc | $408.78 | 2022-2023 | Uplizna |
| Grifols USA, LLC | $388.35 | 2019-2025 | Gamunex-C |
| Sumitomo Pharma America, INC. | $322.74 | 2023-2024 | Aptiom |
| Impel Pharmaceuticals INC. | $322.25 | 2022-2023 | Trudhesa |
| Argenx US, INC. | $308.26 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Biohaven Pharmaceuticals, INC. | $308.08 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $279.28 | 2022 | |
| Adamas Pharmaceuticals, INC. | $263.49 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $252.17 | 2021-2025 | Nuplazid |
| Genzyme Corporation | $240.33 | 2019-2025 | |
| Acorda Therapeutics, INC | $209.20 | 2019-2023 | Inbrija |
| E.R. Squibb & Sons, L.L.C. | $198.68 | 2020-2024 | Zeposia |
| Alexion Pharmaceuticals, INC. | $186.73 | 2019-2025 | Ultomiris, Soliris |
| Avanir Pharmaceuticals, INC. | $182.82 | 2019-2022 | |
| Allergan, INC. | $171.29 | 2019-2021 | |
| Neurelis, INC. | $165.49 | 2020-2025 | Valtoco |
| Abbott Laboratories | $136.75 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $136.05 | 2023-2025 | Hyqvia, Gammagard |
| Janssen Pharmaceuticals, INC | $130.16 | 2021-2023 | Ponvory |
| Tanabe Pharma America, INC. | $113.78 | 2020-2025 | Radicava |
| Avion Pharmaceuticals | $104.64 | 2022-2023 | Dhivy |
| Eisai INC. | $101.99 | 2024-2025 | |
| Axsome Therapeutics, INC. | $100.97 | 2023-2025 | Symbravo, Sunosi |
| Tg Therapeutics, INC. | $83.14 | 2024-2025 | |
| Csl Behring | $81.16 | 2019-2025 | Hizentra |
| Alnylam Pharmaceuticals INC. | $71.53 | 2021-2022 | |
| Impel Pharmaceuticals LLC | $70.97 | 2024-2025 | Trudhesa |
| Sanofi-Aventis U.S. LLC | $63.45 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $59.12 | 2024 | |
| Harmony Biosciences LLC | $53.71 | 2020-2024 | |
| Ani Pharmaceuticals, INC. | $53.17 | 2024 | Purified Cortrophin Gel |
| Aprecia Pharmaceuticals, LLC | $36.49 | 2019 | |
| Vanda Pharmaceuticals INC. | $33.90 | 2025 | Ponvory |
| Livanova USA, INC. | $32.91 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $28.80 | 2022 | |
| Janssen Biotech, INC. | $20.91 | 2025 | |
| Jazz Pharmaceuticals INC. | $18.10 | 2025 | |
| Microtransponder, INC. | $17.72 | 2025 | |
| Currax Pharmaceuticals LLC | $17.69 | 2021 | |
| Mallinckrodt Enterprises LLC | $17.59 | 2019 | |
| Banner Life Sciences, LLC | $16.02 | 2022 | |
| Linus Health, INC. | $15.68 | 2023 | |
| Arbor Pharmaceuticals, INC. | $12.52 | 2021 | |
| Merck Sharp & Dohme LLC | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Mccasland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.